REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Morrisons takeover battle will go to UK auction on Oct. 2

Wed, 29th Sep 2021 09:23

(Adds background)

LONDON, Sept 29 (Reuters) - A $9.5-billion fight for British
supermarket Morrisons will be decided at an auction on
Saturday, when two U.S. private equity groups will go
head-to-head in up to five rounds of bids.

Britain's Takeover Panel said on Wednesday that Clayton,
Dubilier & Rice (CD&R) and Fortress Investment Group had agreed
to settle the matter in a one-day auction.

CD&R, a U.S. private equity firm, started its pursuit of
Britain's fourth-largest grocer in June.

Softbank-backed Fortress entered the fray in July, winning
the backing of the board of Morrisons for bids at 252 pence and
then 270 pence a share.

CD&R returned to trump Fortress with a 285-pence offer,
valuing the supermarket at 7 billion pounds ($9.5 billion).

Given that neither bidder had declared its offer final, the
Takeover Panel said all of the parties had agreed to an auction
process to decide the outcome.

Morrisons shares were trading up 1.3% at 296 pence in early
trading on Wednesday.

The battle for Morrisons is the most high-profile amid a
raft of bids for British companies this year, reflecting private
equity's appetite for cash-generating UK assets.

With more than one bidder increasingly targeting one
company, previously rare auctions have become more frequent.

The most recent on Sept. 22 resulted in a consortium of
funds managed by Ancala Partners and Fiera Infrastructure paying
372 pence a share to buy waste management company Augean, a near
10% rise on the highest offer before the auction.

Other auctions set up this year to decide the fate of
security firm G4S and pharmaceutical company Vectura were
scrapped when one of the parties declared their bid final, a
development that could still scupper the Morrisons tussle.

($1 = 0.7311 pounds)
(Reporting by Paul Sandle; Editing by Kate Holton and
Bernadette Baum)

More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.